Efficacy & Safety of Thrombate III
Efficacious. In clinical trials, Thrombate III has been proven to prevent thromboembolism in patients with hereditary antithrombin deficiency in high-risk situations.1
| |
• |
In clinical trials, none of the patients with a history of thromboembolism who were treated prophylactically with Thrombate III for high-risk procedures developed a thrombotic complication1 |
| |
• |
Thrombate III reversed heparin resistance in two patients with hereditary AT deficiency being treated for thrombosis or thromboembolism1 |
Predictable. Thrombate III is highly purified antithrombin concentrate that gives physicians precise control over antithrombin levels.
| |
• |
Purified to remove other coagulation proteins |
Safe. Thrombate III has a well-established safety profile.
| |
• |
Thrombate III has more than 15 years of post-marketing experience |
| |
• |
More than 100 million IUs have been administered with no reported case of virus transmission |
| |
• |
Thrombate III is pasteurized to inactivate viruses and purified to remove proinflammatory cytokines |
| |
• |
Thrombate III has a low incidence of side effects |
| |
|
|
– |
The most common include dizziness, chest tightness, nausea, and a foul taste in the mouth |
Well Tolerated. The rate of administration of Thrombate III should be adapted to the response of the individual patient, but administration of the entire dose in 10 to 20 minutes is generally well tolerated.
For clinical questions about Thrombate III, please contact Talecris Clinical Communications: 1-800-520-2807.
Reference:
| 1. |
|
Thrombate III [prescribing information]. Research Triangle Park, NC; Talecris Biotherapeutics, Inc.; 2006.
|
Important Safety Information
Thrombate III therapy has demonstrated a low occurrence of side effects. In clinical studies with Thrombate III, the most common side effects were dizziness, chest tightness, nausea, and a foul taste in the mouth. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated. Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C.
Please see full Prescribing Information for Thrombate III.
|